Skip to main content
Article
GABAA Receptors as Targets for the Management of Pain-related Disorders: Historical Perspective and Update.
CNS & Neurological Disorders - Drug Targets (2017)
  • Bradford D Fischer, Rowan University
Abstract
BACKGROUND:
Chronic pain is treated most commonly with opioid analgesics, anti-inflammatory steroids and nonsteroidal anti-inflammatory drugs.
METHOD:
However, these compounds are not uniformly effective and their clinical use is constrained by unwanted side effects. GABAergic neurons are located in spinal nociceptive circuits suggesting that drugs with affinity at these receptors, including benzodiazepine-like drugs, may provide an alternative to opioids for the treatment of pain. However, systemically administered conventional benzodiazepines fail to produce antihyperalgesic effects, likely due to their concurrent sedative properties.
RESULTS:
Recent evidence suggests that by targeting specific benzodiazepine-sensitive GABAA; receptor subtypes, the sedative properties of benzodiazepines can be circumvented and these compounds may be useful alternatives to opioids for the treatment of chronic pain.
CONCLUSION:
The present review provides an overview of the GABAA; receptor subtypes involved in pain transmission as well as implications for the development of analgesic medications.
Keywords
  • Antihyperalgesic; GABAA; benzodiazepine; disorders; drug development; pain
Publication Date
2017
DOI
10.2174/1871527316666170207155149
Citation Information
Bradford D Fischer. "GABAA Receptors as Targets for the Management of Pain-related Disorders: Historical Perspective and Update." CNS & Neurological Disorders - Drug Targets Vol. 16 Iss. 6 (2017) p. 658 - 663 ISSN: 1871-5273
Available at: http://works.bepress.com/bradford-fischer/7/
Creative Commons license
Creative Commons License
This work is licensed under a Creative Commons CC_BY International License.